Helicos, the Aim of the $1,000 Genome (HLCS)
Helicos BioSciences (NASDAQ:HLCS) is up and up sharply on two issues. Late yesterday the company said it had sequenced a human genome. A New York Times article highlighted its ability to decode the...
View ArticleHelicos BioSciences (HLCS) Is On The Move Again, To Nowhere
Helicos (HLCS) got some good news when a scientist who was one of the firm’s founders said he had mapped the entire personal genome using one of the HLCS products. The stock jumped from about $.70 to...
View ArticleHelicos BioSciences (HLCS) Moves Up On Plans To Restructure
Helicos BioSciences (HLCS) is up over 20% to $7.85 on a possible restructuring. The shares still trade well below their 52-week high of $4.18. HLCS is actively engaged in discussions with potential...
View ArticleHelicos BioSciences (HLCS) Stays Volatile
Helicos BioSciences (HLSC) is up 30% on news that the RIKEN Yokohama Institute Omics Science Center (OSC) has agreed to purchase four Helicos™ Genetic Analysis Systems. The transaction represents the...
View ArticleHelicos BioSciences (HLCS) Soars, But Will Probably Sell Off
Helicos BioSciences (HLCS) is up 32% to $3.20 very near its 52-week high. The period low is $.21 so consider the shares over-bought and ripe for a sell-off, particularly because today’s news is not...
View ArticleHelicos (HLCS) Picks Up A Little Cash
Helicos BioSciences (NASDAQ:HLCS) picked up a little extra cash. According to an update passed out by the company today, sales of the Helicos Genetic Analysis System more than doubled last quarter....
View ArticleHelicos Biosciences (HLCS) To Raise Funds
Helicos Biosciences (NASDAQ:HLCS) is getting hammered this morning. that it has priced a registered direct offering of 6.4 million units, at a price of $1.00 per unit, for gross proceeds of $6.4...
View ArticleWhy Celera’s Buyout Makes Sense (CRA, DGX, HGSI, AFFX, GHDX, GNOM, ROSG, HLCS)
If you would have said ten years ago that Celera Corporation (NASDAQ: CRA) would be acquired by Quest Diagnostics Inc. (NYSE: DGX), most investors would have said that you were off your rocker. Celera...
View Article
